A practical reference on REV-ERB: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2025-11-21. Anything still debated is marked as such rather than presented as settled.
Research interest in SR9009 grew from studies showing improved running endurance in mice after short treatment periods. Those experiments linked the compound to increased mitochondrial content and fatty acid oxidation in muscle, but the findings come from animal models and specific dosing schedules. Independent replication has been limited, and the pathways connecting REV-ERB activation to exercise performance are still being mapped. Whether similar responses occur in humans is an open question.
SR9009 is often grouped with compounds studied for circadian and metabolic regulation rather than with classical anabolic steroids. Its interactions with nuclear receptors differ from those of androgen receptor ligands, and its proposed mechanisms involve transcriptional control rather than direct hormone signaling. Some sources classify it as a metabolic modulator because of observed effects on energy utilization. The distinction matters for regulation and for interpreting research results across different compound classes.
SR9009 is frequently discussed alongside other REV-ERB ligands, including synthetic agonists and natural heme-related molecules. Its selectivity for REV-ERB over related nuclear receptors has been measured in binding and reporter assays, though off-target activity at higher concentrations is possible. The compound is prohibited in sport by the World Anti-Doping Agency, and it is not approved for any medical use in major jurisdictions. Products sold online may be labeled as research chemicals, and their identity and purity are not guaranteed by regulatory review.
SR9009 is a synthetic small molecule that acts on the nuclear receptors REV-ERBα and REV-ERBβ. These receptors are part of the circadian clock machinery and normally repress transcription of certain target genes. In laboratory research, SR9009 is used as a chemical tool to study how REV-ERB activity influences metabolism, inflammation, and daily biological rhythms. The compound is not an approved medicine, and its effects in humans remain largely uncharacterized. It is often described as an investigational agent rather than a therapeutic product.
REV-ERB proteins typically suppress gene expression by recruiting corepressor complexes to DNA response elements. SR9009 binds these receptors and strengthens that repressive action in cell-based assays. Studies in rodents have reported changes in lipid handling, mitochondrial function, and exercise capacity after treatment. Such findings are often cited as evidence for metabolic effects, but species differences and limited pharmacokinetic data make direct translation to humans uncertain. Researchers continue to examine which effects are robust and which depend on specific experimental conditions.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C20H24ClN3O4S | Reported for the free base |
| Molecular weight | 437.9 g/mol | Calculated from the formula |
| Primary target | REV-ERBα and REV-ERBβ | Nuclear receptors involved in circadian regulation |
| Solubility | Soluble in DMSO and ethanol | Poorly soluble in water |
| Typical storage | -20 °C, desiccated | Protect from light and moisture |
SR9009 is generally described as poorly soluble in water and more soluble in organic solvents such as dimethyl sulfoxide and ethanol. Stock solutions are commonly prepared in an organic solvent before dilution into an aqueous buffer or vehicle. Precipitation can occur if the organic fraction is reduced too quickly or if the final concentration exceeds the compound's solubility limit. Sonication or gentle warming may aid dissolution in some protocols, but excessive heat can promote degradation. Container material and pH can also influence observed solubility.
For long-term storage, SR9009 is typically kept as a solid at low temperature, protected from moisture and light. Desiccated conditions limit hydrolysis, while opaque containers reduce photochemical breakdown. Solutions are less stable than solids and are often stored frozen in aliquots to avoid repeated freeze-thaw cycles. Stability data are not standardized across all suppliers, so users should rely on certificate-of-analysis information when available. Degradation may appear as color change, precipitate, or decreased chromatographic purity.
Detection of SR9009 in biological samples usually relies on liquid chromatography coupled to tandem mass spectrometry. This approach separates the compound from matrix components and identifies it by mass transitions. Because SR9009 can undergo metabolism, laboratories often look for both parent drug and specific metabolites. Sample preparation may involve protein precipitation or solid-phase extraction. Method validation examines sensitivity, carryover, and interference from related substances, and reference standards are required for accurate calibration.
Storage recommendations for SR9009 reference material typically specify a freezer at -20 °C or lower, with protection from moisture and light. Repeated freeze-thaw cycles can degrade small molecules and introduce variability. Stock solutions in dimethyl sulfoxide are often aliquoted to avoid repeated handling. Stability studies may examine degradation under heat, humidity, and light exposure. The compound's thiophene and nitro groups can participate in reactions that alter analytical signals over time, so such changes affect quantitative results.
== Fibrous types == Fiber types found in the extracellular matrix are collagen fibers, elastic fibers, and reticular fibers. Ground substance is a clear, colorless, and viscous fluid containing glycosaminoglycans and proteoglycans allowing fixation of collagen fibers in intercellular spaces. Examples of non-fibrous connective tissue include adipose tissue (fat) and blood. Adipose tissue gives "mechanical cushioning" to the body, among other functions. Although there is no dense collagen network in adipose tissue, groups of adipose cells are kept together by collagen fibers and collagen sheets in order to keep fat tissue under compression in place (for example, the sole of the foot). Both the ground substance and proteins create the matrix for connective tissue. Type I collagen is present in many forms of connective tissue, and makes up about 25% of the total protein content of the mammalian body.
== Structure == A tendon is made of dense regular connective tissue, whose main cellular components are special fibroblasts called tendon cells (tenocytes). Tendon cells synthesize the tendon's extracellular matrix, which abounds with densely-packed collagen fibers. The collagen fibers run parallel to each other and are grouped into fascicles. Each fascicle is bound by an endotendineum, which is a delicate loose connective tissue containing thin collagen fibrils and elastic fibers. A set of fascicles is bound by an epitenon, which is a sheath of dense irregular connective tissue. The whole tendon is enclosed by a fascia. The space between the fascia and the tendon tissue is filled with the paratenon, a fatty loose connective tissue. Normal healthy tendons are anchored to bone by Sharpey's fibres.
=== Early history of food applications === The 10th-century Kitab al-Tabikh includes a recipe for a fish aspic, made by boiling fish heads. A recipe for jelled meat broth is found in Le Viandier, written in or around 1375. In 15th century Britain, cattle hooves were boiled to produce a gel. By the late 17th century, the French inventor Denis Papin had discovered another method of gelatin extraction via boiling of bones. An English patent for gelatin production was granted in 1754. In 1812, the chemist Jean-Pierre-Joseph d'Arcet further experimented with the use of hydrochloric acid to extract gelatin from bones, and later with steam extraction, which was much more efficient. The French government viewed gelatin as a potential source of cheap, accessible protein for the poor, particularly in Paris. Food applications in France and the United States during the 19th century appear to have established the versatility of gelatin, including the origin of its popularity in the US as Jell-O. In the mid-19th century, the American industrialist and inventor, Peter Cooper, registered a patent for a gelatin dessert powder he called "Portable Gelatin", which only needed the addition of water. In the late 19th century, Charles and Rose Knox set up the Charles B. Knox Gelatin Company in New York, which promoted and popularized the use of gelatin.
=== Early history of food applications === The 10th-century Kitab al-Tabikh includes a recipe for a fish aspic, made by boiling fish heads. A recipe for jelled meat broth is found in Le Viandier, written in or around 1375. In 15th century Britain, cattle hooves were boiled to produce a gel. By the late 17th century, the French inventor Denis Papin had discovered another method of gelatin extraction via boiling of bones. An English patent for gelatin production was granted in 1754. In 1812, the chemist Jean-Pierre-Joseph d'Arcet further experimented with the use of hydrochloric acid to extract gelatin from bones, and later with steam extraction, which was much more efficient. The French government viewed gelatin as a potential source of cheap, accessible protein for the poor, particularly in Paris. Food applications in France and the United States during the 19th century appear to have established the versatility of gelatin, including the origin of its popularity in the US as Jell-O. In the mid-19th century, the American industrialist and inventor, Peter Cooper, registered a patent for a gelatin dessert powder he called "Portable Gelatin", which only needed the addition of water. In the late 19th century, Charles and Rose Knox set up the Charles B. Knox Gelatin Company in New York, which promoted and popularized the use of gelatin.
== Development == Valve entered the VR space in the mid-2010s, demonstrating the Robot Repair VR demo at the 2015 Game Developers Conference. The following year, they partnered with HTC and released the HTC Vive, along with a series of "experiments" called The Lab. Plans to develop a new Half-Life game began after this, and Valve started a project named "The Prototype", helmed by Robin Walker. Concerned that other companies would limit the scope of VR technology, Walker felt that Valve had a duty as a game developer to get involved. Onboarding others in Hawaii opened up two more projects alongside the Index, those being the A.R.T.I. project and SimTrek. These plans ultimately fell through. Walker envisioned a controller that allowed for hand tracking, rather than just functioning as a remote control. The newly focused project developed a slimmed down headset and controllers, named the "Knuckles", that allowed for "believable" hands whilst in VR. Development kits for the Knuckles, codenamed "EV2", were showcased in 2018. Design elements, such as the large trackpad, were adapted from the HTC Vive controllers. These were later toned down, with a thumbstick implemented and a "track button", which is a tracking surface that sat between the stock and now centralised buttons. Hand sizes were considered so that the 5th to 95th percentiles would not have issues holding the Knuckles. Extra size customisations were included, as was a strap.
Sources: en.wikipedia.org
== History == Rosiglitazone was approved by the US FDA in 1999 and by the EMA in 2000; the EMA however required two postmarketing studies on longterm adverse effects, one for chronic heart failure and the other for cardiovascular effects.
== Honors and awards == Albania: On 20 June 2008 received a copy of the key of the city of Tirana on the occasion of his state visit to Albania. Also on 20 June, Thaçi was awarded the Honorary Citizen of the city of Vlorë for his "historic role in making Kosovo an independent state". In January 2015 Thaçi was awarded the Doctor Honoris Causa from the University of Tirana for his contribution in peace-building in Western Balkans, promoting the process of European integration and achieving the historic Brussels Agreement with Serbia. On 4 October 2016 he was awarded honorary citizenship of Shkodër in a ceremony led by the mayor of the northern Albanian city. Switzerland: On 1 July 2012, Thaçi received a doctor honoris causa as a doctor of international relations from the Geneva School of Diplomacy. Montenegro: On 4 April 2015, on Ulcinj Day, Thaçi received the title of Honorary Citizen of Ulcinj by the town's municipal government.
==== Trigger (induction) ==== Platelet activation begins seconds after adhesion occurs. It is triggered when collagen from the subendothelium binds with its receptors (GPVI receptor and integrin α2β1) on the platelet. GPVI is associated with the Fc receptor gamma chain and leads via the activation of a tyrosine kinase cascade finally to the activation of PLC-gamma2 (PLCG2) and more calcium release. Tissue factor also binds to factor VII in the blood, which initiates the extrinsic coagulation cascade to increase thrombin production. Thrombin is a potent platelet activator, acting through Gq and G12. These are G protein-coupled receptors and they turn on calcium-mediated signaling pathways within the platelet, overcoming the baseline calcium efflux. Families of three G proteins (Gq, Gi, G12) operate together for full activation. Thrombin also promotes secondary fibrin-reinforcement of the platelet plug. Platelet activation in turn degranulates and releases factor V and fibrinogen, potentiating the coagulation cascade. Platelet plugging and coagulation occur simultaneously, with each inducing the other to form the final fibrin-crosslinked thrombus.
=== Post–Cold War foreign policy uncertainty in the United States === By the early 1990s, the United States had developed a complex global presence but lacked a shared framework for defining post–Cold War threats, interests, and priorities. Policymakers debated whether American leadership should emphasize restraint, engagement, or continued global activism, causing many to criticize the period's self-indulgence, attempts to reorganize the Islamic world, and the failure to integrate the former Soviet Union into NATO. The United States had established a complex global presence by the 1990s and policymakers felt that some structure to explain the "threats, interests and priories" that guide foreign policy was needed, but there was no agreement on how to proceed. Anthony Lake has said that attempts at doctrine-making during this period risked introducing "neo-know-nothing" isolationism or what he termed "irrational" ideas. The goal then of Bush Sr. and Clinton during their terms in office was to develop foreign policy objectives that would support consensus rather than accelerate fragmentation inside America's sphere of influence, ideological confrontation, or rigid doctrine building.
Sources: en.wikipedia.org
It is a synthetic REV-ERB agonist used mainly in preclinical research. It is not an approved medicine for human use.
It binds to REV-ERBα and REV-ERBβ, nuclear receptors involved in circadian and metabolic gene regulation. This can alter transcription of genes related to lipid and glucose metabolism in experimental models.
No controlled human trials have established that effect. Endurance findings come primarily from rodent studies, and human responses remain unknown.
SR9009 is a synthetic research compound that binds and modulates the nuclear receptors REV-ERBα and REV-ERBβ. It is used in laboratory studies of circadian biology and metabolism, not as an approved medicine. It is also known by the informal name Stenabolic.